<DOC>
	<DOCNO>NCT00162266</DOCNO>
	<brief_summary>This study conduct assess safety tolerability Abatacept combine Methotrexate participant active rheumatoid arthritis ( RA ) . The secondary objective assess efficacy , pharmacodynamic marker activity , immunogenicity Abatacept combine Methotrexate .</brief_summary>
	<brief_title>Abatacept With Methotrexate- Phase IIB</brief_title>
	<detailed_description>All participant complete 12-month double-blind study period eligible continue open-label study . Participants receive placebo , Abatacept 2 mg/kg , Abatacept 10 mg/kg double-blind study . Participants receive placebo double-blind study switch 1:1 continued treatment placebo Abatacept 2 mg/kg . Participants receive Abatacept 2 mg/kg Abatacept 10 mg/kg continue double-blind study dosage . After result double-blind period become available , participant switch weight-tiered 10 mg/kg dose Abatacept . Open label study design : Single group assignment , Single arm , Open label ,</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Double blind study phase : 1 . Males female ( nurse pregnant ) , least 18 year age . Women child bear potential ( WOCBP ) eligible practice effective contraceptive measure 2 . Subjects must meet criterion American Rheumatism Association ( 1987 ) diagnosis rheumatoid arthritis American College Rheumatology ( 1991 ) functional class I , II , III 3 . Subjects take Methotrexate ( 1030 mg weekly ) least 6 month , stable dose 28 day prior treatment 4 . Washout/drug stabilization requirement ( except Methotrexate ) [ Informed consent must sign make change RA therapy change solely purpose study ] . Leflunomide Infliximab already discontinue least 60 day prior enrollment ( prior signing informed consent ) total 90 day prior treatment . All Disease Modifying AntiRheumatic Drugs ( DMARDs ) ( except Methotrexate ) withdraw least 28 day prior treatment Oral corticosteroid treatment reduce equivalent 10 mg less prednisone daily stabilize least 28 day prior enrollment 5 . Eligibility subject study base disease activity antirheumatic treatment initial visit : Methotrexate monotherapy : Subject receive Methotrexate , steroid , Nonsteroidal antiinflammatory drug ( NSAIDs ) require washout Combination therapy : Subject receive Methotrexate combination another DMARD ( ) require washout At entry , Methotrexate monotherapy must disease activity : 10 swollen joint ( 66 joint count ) 12 tender joint ( 68 joint count ) C reactive protein ( CRP ) ≥.1 mg/dL ( 10 mg/L ) `` Screening '' visit At entry , combination therapy must disease activity ( subject satisfy ) : 6 swollen joint ( 66 joint count ) 8 tender joint ( 68 joint count ) No restriction Creactive protein ( CRP ) In addition All subject combination therapy entry must undergo 28 day washout period DMARDs Methotrexate . After washout/drug stabilization prior randomization subject must : 10 swollen joint ( 66 joint count ) 12 tender joint ( 68 joint count ) C reactive protein ( CRP ) ≥ 1 mg/dL ( 10 mg/L ) 6 . Subject willing participate study willing sign inform consent Open label study phase : Participants complete initial short term portion ( double blind ) study Double blind study phase : 1 . Subjects time receive treatment BMS188667 ( Abatacept ) 2 . Subjects within 30 day Day 1 visit receive treatment investigational drug 3 . Subjects active vasculitis major organ system ( except subcutaneous rheumatoid nodule ) 4 . Current symptom severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , pulmonary , cardiac , neurological , cerebral disease . Concomitant medical condition opinion investigator might place subject unacceptable risk participation study 5 . Mammogram require investigation biopsy lead diagnosis clinically significant abnormality . Complete evaluation lesion require initiation dose 6 . Subjects history cancer within last five year ( nonmelanoma skin cell cancer cure local resection ) 7 . Subjects history clinically significant drug alcohol abuse , admit consumption 1 alcoholic drink per day 8 . Subjects evidence ( assessed investigator ) active latent bacterial viral infection time potential enrollment , include subject evidence Human Immunodeficiency Virus ( HIV ) infection , hepatitis B C infection 9 . Subjects serious chronic infection pneumonia , pyelonephritis , renal infection , chest infection bronchiectasis , sinusitis previous 3 month 10 . Subjects active tuberculosis require treatment within previous 3 year 11 . Subjects opportunistic infection herpes zoster cytomegalovirus ( CMV ) within previous 2 month 12 . Subjects severe asthma define &gt; 3 emergency room admission last year &gt; 3 treatment oral steroid asthma last year 13 . A history either angioedema anaphylaxis associate reaction drug 14 . Subjects follow laboratory value : Hemoglobin &lt; 8.5 g/dL White blood cell &lt; 3000/mm3 Platelets &lt; 100,000/mm3 Serum creatinine &gt; 2 time upper limit normal Serum Alanine aminotransferase ( ALAT ) Aspartate aminotransferase ( ASAT ) &gt; 2 time upper limit normal Any lab value opinion investigator might place subject unacceptable risk participation study Open label study phase : Participants must continue meet inclusion/exclusion criterion short term ( double blind ) phase protocol except subject receive Abatacept</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>